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Platelet Distribution Width and Mean Platelet Volume Are Not 
Correlated with the Disease Activity Indices of Ankylosing 
Spondylitis 
Sejin Byun, Seung Min Jung, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 
Objective. We investigated the association of platelet distribution width (PDW) and mean platelet volume (MPV) with disease 
activity indices of ankylosing spondylitis (AS) in patients whose laboratory results or medical conditions would not affect PDW 
and MPV levels. Methods. We analysed demographic and laboratory data of 88 patients with AS. On the same day as the labo-
ratory tests were done, we assessed AS disease activity using the Bath Ankylosing Spondylitis Disease Activity Index, Bath 
Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Patients Global Score and Ankylosing Spondylitis 
Disease Activity Score (ASDAS), including erythrocyte sedimentation rate (ESR) (ASDAS-ESR) and C-reactive protein (CRP) 
(ASDAS-CRP). The association was analyzed by linear regression. Results. The median age of 88 patients was 38.0 years and 
the median length of observation was 5.5 years. The median platelet count was 266,500.0/μL, the median PDW was 10.7 fL 
and the median MPV 9.6 fL. The median ESR was 19.0 mm/hr and CRP was 2.5 mg/L. Among acute reactants, only CRP was 
negatively correlated with MPV, but not PDW (r=−0.218, p＜0.041). However, both PDW and MPV were not significantly 
correlated with any disease activity index of AS. On multivariate linear regression analysis, only the length of observation was 
significantly correlated with MPV (β=0.224, p＜0.044). Conclusion. PDW and MPV were not potent surrogate markers to re-
flect AS activity, with potential confounding strictly controlled, to affect MPV and PDW levels.  (J Rheum Dis 2017;24:143-148)
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INTRODUCTION
Ankylosing spondylitis (AS) is a systemic autoimmune 
disease, which is characterised by both articular and ex-
tra-articular features [1]. In the clinical settings, eryth-
rocyte sedimentation rate (ESR) or C-reactive protein 
(CRP) are widely measured to assess the inflammatory 
burdens in many rheumatic diseases, but, in AS patients, 
either ESR or CRP alone has not been considered good 
predictors to reflect AS activity [2,3]. Moreover, on the 
basis of clinical symptoms, function and spinal mobility, 
various tools to assess the disease activity of AS have been 
introduced and used including bath ankylosing spondylitis 
disease activity index (BASDAI), bath ankylosing spon-
dylitis functional index (BASFI) and bath ankylosing 
spondylitis patients global score (BAS-G), Bath 
Ankylosing Spondylitis Metrology Index. However, these 
indices also have a limitation that they include no ob-
jective laboratory results [4-7]. In 2009, ankylosing spon-
dylitis disease activity score (ASDAS) with ESR 
(ASDAS-ESR) and CRP (ASDAS-CRP), including both 
clinical and laboratory items, was proposed [8]. 
Nevertheless, a need for a single and convenient serum 
marker to predict AS activity has been still raised to date. 
Platelet distribution width (PDW) and mean platelet 
volume (MPV) are the surrogate indices to reflect size 
distribution of platelets in peripheral circulation. They 
can be increased in idiopathic thrombocytopenic purpura 
and myeloproliferative disorder, and decreased in aplastic 
anaemia [9,10]. In addition, there were reports that PDW 
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Figure 1. Selection of the study 
population. HbA1c: haemoglo-
bin A1c, INR: international nor-
malized ratio.
and MPV can also reflect the inflammatory burdens in 
various pathological situations, such as abnormal glucose 
metabolism, chronic liver diseases, chronic kidney dis-
eases, hypertension, dyslipidaemia, cardiovascular dis-
eases, and rheumatoid arthritis [11-17]. However, pre-
vious studies regarding the clinical efficiency of PDW and 
MPV to reflect AS activity reported inconsistent results, 
and furthermore, they did not strictly control the con-
founding factors to affect PDW and MPV [18-22]. In this 
study, we investigated whether PDW and MPV can reflect 
disease activity indices of AS in patients without abnor-
mal laboratory results or medical conditions to affect 
PDW and MPV levels. 
MATERIALS AND METHODS
Patients
We consecutively screened and enrolled 141 patients 
with AS in this study, from March 2015 to October 2015, 
by the inclusion criteria as follows: (1) patients who ful-
filled modified New York criteria for AS and who had been 
first diagnosed with AS at the Division of Rheumatology, 
Yonsei University College of Medicine, Severance Hospital 
[23]; (2) patients who had no medical conditions to affect 
PDW and MPV, such as abnormal glucose metabolism, 
chronic liver diseases, chronic kidney diseases, hyper-
tension, dyslipidaemia, cardiovascular diseases, rheuma-
toid arthritis, and concurrent infection or hematologic 
disorders identified by 10th revised international classi-
fication of diseases [11-17,24,25]; (3) patients who had 
never received medications for diseases above searched 
by the Korean Drug Utilization Review system; (4) pa-
tients who had not received blocking agents against tu-
mour necrosis factor (TNF), which are one of factors in-
fluencing the maturation of thrombopoietic cells and re-
lease of platelet into the circulation [26]. (5) Patients who 
had no concurrent infection and malignancy to enhance 
acute phase reactants levels; (6) patients who gave in-
formed consent to their participation; (7) patients who 
took the assessment of disease activity indices of AS by 
independent physician on the same day of laboratory 
tests; (8) patients having laboratory results fulfilling the 
normal reference range as described in Figure 1 [27]. We 
excluded 28 patients having medical conditions or having 
received anti-TNF agents to affect PDW and MPV, and we 
further excluded 32 according to the inclusion criteria 
based on laboratory results (Figure 1). Finally, we ana-
lysed data of 88 patients with AS in this study. This study 
was approved by the Institutional Review Board of 
Severance Hospital. Informed consent was obtained from 
all patients (4-2015-0826).
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Table 1. Baseline characteristics of patients with ankylosing 
spondylitis (n=88)
Variable Value
Demographic data 
  Age (yr) 38.0 (15.8)
  Male gender    68 (77.3)
  Follow-up duration (yr) 5.5 (8.5)
  Smoking    36 (40.9)
  BMI (kg/m2) 24.0 (5.0)
Platelet information 
  Platelet×103 (/mm3) 266.5 (70.3)
  PDW (fL) 10.7 (1.9)
  MPV (fL) 9.6 (1.0)
Other laboratory results 
  White blood cell (/mm3) 7,495.0 (2,650.0)
  Haemoglobin (g/dL) 14.9 (2.3)
  Prothrombin time (INR) 0.9 (0.1)
  Fasting glucose (mg/dL) 95.5 (12.8)
  HbA1c 5.5 (0.4)
  Blood urea nitrogen (mg/dL) 13.9 (4.5)
  Creatinine (mg/dL) 0.8 (0.2)
  Albumin (mg/dL) 4.5 (0.5)
  Alkaline phosphatase (IU/L) 70.0 (26.0)
  Aspartate aminotransferase (IU/L) 20.0 (9.0)
  Alanine aminotransferase (IU/L) 18.0 (17.0)
  Total cholesterol (mg/dL) 192.0 (40.3)
  High density cholesterol (mg/dL) 49.0 (16.0)
   Low density cholesterol (mg/dL) 105.0 (23.2)
  Triglyceride (mg/dL) 179.0 (184.3)
Acute reactants and disease activity indices
  ESR (mm/h) 19.0 (25.0)
  CRP (mg/L) 2.5 (5.3)
  ASDAS-ESR 2.3 (1.5)
  ASDAS-CRP 2.0 (1.5)
  BASDAI 3.6 (2.4)
  BAS-G 3.0 (4.0)
  BASFI 1.7 (3.3)
Values are expressed as median (interquartile range, IQR) and
number (%). BMI: body mass index, PDW: platelet distribution 
width, MPV: mean platelet volume, INR: international nor-
malized ratio, HbA1c: haemoglobin A1c, ESR: erythrocyte 
sedimentation rate, CRP: C-reactive protein, ASDAS: ankylosing 
spondylitis disease activity score, BASDAI: bath ankylosing 
spondylitis disease activity index, BAS-G: bath ankylosing 
spondylitis patient global score, BASFI: bath ankylosing 
spondylitis disease activity functional index. 
Data collection and assessment of the disease 
activity of AS
On the same day of laboratory tests, we measured blood 
pressure as well as height and weight to calculate body 
mass index (BMI). Smoking history was assessed via 
self-reported questionnaire for patients. Age, gender and 
the follow-up duration were obtained as demographic 
data. We described the items of laboratory tests in Table 
1. Ethylenediaminetetraacetic acid was currently used as 
anticoagulant. PDW and MPV were routinely measured 
and calculated by automatic cell counters after 120 mi-
nutes from the time of blood collection in all cases in or-
der to minimize the chance of platelet swelling. We as-
sessed the disease activity of AS using BASDAI, BASFI, 
and BAS-G [4-6]. We also collected ASDAS-ESR and 
ASDAS-CRP by the equations as described in a previous 
study [8]. 
Statistical analysis 
All statistical analyses were conducted using SPSS soft-
ware (version 23 for Windows; IBM Corp., Armonk, NY, 
USA). Results of continuous variables were expressed as 
median (interquartile range). Univariate analysis of the 
association of variables with ASDAS-ESR and 
ASDAS-CRP was performed using linear regression test. 
Standardized correlation coefficient was assessed by a 
multivariate linear regression test using variables with 
significant differences on univariate analysis. The p-val-
ues less than 0.05 were considered to indicate statistical 
significance. 
RESULTS
Baseline characteristics of patients with ankylosing 
spondylitis 
The baseline characteristics are summarized in Table 1. 
The median age of 88 participants (68 men and 20 wom-
en) was 38.0 years and the median follow-up duration 
was 5.5 years. The median BMI was 24.0 kg/m2. Thirty-six 
patients reported the smoking history. The median plate-
let count was 266,500.0/μL and the median PDW and 
MPV were 10.7 fL and 9.6fL, respectively. The median 
ESR and CRP were 19.0 mm/hr and 2.5 mg/L. The me-
dian BASDAI, BAS-G, and BASFI were assessed as 3.6, 
3.0 and 1.7, respectively. And the median ASDAS-ERS 
and ASDAS-CRP were 2.3 and 2.0. 
Univariate and multivariate analyses of PDW and 
other variables
We analysed the association of PDW with acute phase 
reactants and the disease activity indices of AS. Univariate 
linear regression analysis revealed that PDW was inversely 
correlated with platelet count (r=−0.369, p＜0.001), and 
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Table 2. Univariate and multivariate analysis of either PDW or MPV and other continuous variables
Variable
Univariate analysis Multivariate analysis
VIFRegression
coefficient
(Crude B)
Correlation
coefficient
(R=β)
p-value
Standardized 
β*
95% 
confidential 
interval
p-value
Analysis of PDW
  Demographic data 
      Age (yr) 0.031 0.205 0.056 0.098 −0.015, 0.044 0.326 1.093
      Follow-up duration (yr) 0.045 0.179 0.095 - - - -
      BMI (kg/m2) 0.053 0.096 0.893 - - - -
  Platelet information 
      Platelet×103 (/mm3) −0.011 −0.369 ＜0.001 - - - -
      MPV (fL) 0.920 0.463 ＜0.001 - - - -
  Acute reactants and the 
    disease activity indices
      ESR (mm/h) −0.008 −0.078 0.470 - - - -
      CRP (mg/L) −0.034 −0.170 0.114 - - - -
      ASDAS-ESR 0.091 0.051 0.635 - - - -
      ASDAS-CRP 0.165 0.094 0.382 −0.200  −0.902, 0.204 0.213 2.797
      BASDAI 0.193 0.200 0.062 0.284 −0.032, 0.581 0.079 2.818
      BAS-G 0.058 0.079 0.467 - - - -
      BASFI −0.003 −0.008 0.948 - - - -
Analysis of MPV
  Demographic data 
      Age (yr) 0.021 0.274 0.010 0.129 −0.006, 0.025 0.209 1.176
      Follow-up duration (yr) 0.037 0.293 0.006 0.175 −0.003, 0.048 0.089 1.170
      BMI (kg/m2) 0.032 0.114 0.290 - - - -
  Platelet information 
      Platelet×103 (/mm3) −0.003 −0.236 0.027 - - - -
      PDW (fL) 0.233 0.463 ＜0.001 - - - -
  Acute reactants and the 
    disease activity indices
      ESR (mm/h) 0.001 0.018 0.869 - - - -
      CRP (mg/L) −0.022 −0.218 0.041 - - - -
      ASDAS-ESR 0.075 0.083 0.440 - - - -
      ASDAS-CRP 0.123 0.140 0.193 0.020 −0.261, 0.296 0.901 2.882
      BASDAI 0.084 0.173 0.108 0.068 −0.122, 0.189 0.672 2.947
      BAS-G 0.051 0.039 0.198 - - - -
      BASFI 0.018 0.084 0.491 - - - -
Multivariate analyses for PDW were adjusted for age, ASDAS-CRP and BASDAI. We did not include MPV in multivariate analysis 
in order not to confound the interpretation of statistical results, because MPV is a variable closely correlated with PDW. Multivariate
analyses for MPV were adjusted for age, disease duration, ASDAS-CRP and BASDAI. We did not include PDW in multivariate 
analysis in order not to confound the interpretation of statistical results, because PDW is a variable closely correlated with MPV. 
PDW: platelet distribution width, MPV: mean platelet volume, VIF: variance inflation factor, BMI: body mass index, ESR: 
erythrocyte sedimentation rate, CRP: C-reactive protein, ASDAS: ankylosing spondylitis disease activity score, BASDAI: bath 
ankylosing spondylitis disease activity index, BAS-G: bath ankylosing spondylitis patient global score, BASFI: bath ankylosing 
spondylitis disease activity functional index, -: not applicable.
positively correlated with MPV (r=0.463, p＜0.001). 
However, there was no significant correlation of PDW 
with acute reactants and the disease activity indices of AS 
(Table 2). We did not include MPV in multivariate analy-
sis in order not to confuse the interpretation of statistical 
results, because MPV is a variables closely correlated with 
PDW. Therefore, we could not perform a multivariate lin-
ear regression analysis. 
PDW and MPV in AS
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Univariate and multivariate analyses of MPV and 
other variables
We analysed the association of MPV with acute phase re-
actants and the disease activity indices of AS. Univariate 
linear regression analysis discovered that MPV was in-
versely correlated with platelet count (r=−0.236, 
p=0.027) and positively correlated with PDW (r=0.463, 
p＜0.001). Also MPV was significantly correlated with 
age and the follow-up duration (r=0.274, p=0.010, and 
r=0.293, p=0.006). Among acute reactants and the dis-
ease activity indices of AS, only CRP was negatively corre-
lated with MPV (r=−0.218, p=0.041) (Table 2). Similar 
to the analysis of PDW, we did not include PDW in multi-
variate analysis in order not to confound the inter-
pretation of statistical results, because PDW is a variables 
closely correlated with MPV. On multivariate linear re-
gression analysis, only the follow-up duration was sig-
nificantly correlated with MPV (β=0.224, p=0.044) 
(Table 2). 
DISCUSSION
The aim of this study was to confirm whether PDW and 
MPV can reflect disease activity indices of AS in patients 
without abnormal laboratory results or medication con-
ditions to affect PDW and MPV levels, because there have 
been discrepancies among previous studies, the positive 
vs. negative association of MPV with AS activity [18-20]. 
Meanwhile, other previous study reported that PDW and 
MPV were not correlated with AS activity [21,22]. We as-
sumed that the diverse confounding factors to affect 
PDW and MPV levels might result in these discrepancies 
[11-17,24-26]. With these reasons, in the present study, 
we excluded patients with AS who had abnormal labo-
ratory results, and who had medical conditions such as 
hematologic diseases or history of medication ad-
ministered affecting PDW and MPV such as antiplatelets 
[25,28] (data not shown). And in this study, we found 
that PDW and MPV were not associated with not only 
acute reactants, but also disease activity indices of AS af-
ter the adjustment of the confounding factors.
We investigated that PDW an MPV may differ between 
active and inactive groups based on ASDAS-ESR and 
ASDAS-CRP. When we divided 88 AS patients into the 
two groups according to ASDAS-ESR of 2.1, 59 patients 
were assigned to active group. The two groups had stat-
istically even demographic data. We found no significant 
differences in both PDW and MPV between the groups. 
Also, when we divided 88 AS patients into the two groups 
according to ASDAS-CRP of 2.1, 45 patients were as-
signed to active group. There were no significant differ-
ences in demographic data between the two groups. 
Similar to the results based on ASDAS-ESR, we observed 
no significant differences in both PDW and MPV between 
the groups. Taken together, we concluded that PDW and 
MPV were not potent surrogate markers to reflect AS ac-
tivity, under the strict control of the confounding factors 
to affect MPV and PDW levels. The strength of our study 
is to strictly exclude patients with AS, who had abnormal 
laboratory results, and who had medical conditions or 
history of medication administered affecting PDW and 
MPV levels. Our study had several issues. The serial fol-
low-up results of PDW and MPV as well as the disease ac-
tivity indices of AS were not available due to a cross-sec-
tional study. Also the number of patients with AS was not 
large enough to validate our results. We plan to serially 
measure PDW and MPV along with the disease activity 
indices of AS in the more number of patients.
CONCLUSION
The aim of this study was to confirm whether PDW and 
MPV can reflect disease activity indices of AS in patients 
without abnormal laboratory results or medication con-
ditions to affect PDW and MPV levels. And we found that 
PDW and MPV were not potent surrogate markers to re-
flect AS activity, under the strict control of the confound-
ing factors. 
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